Self-Reported Medication Adherence and Symptom Experience in Adults With HIV

The Journal of the Association of Nurses in AIDS Care: JANAC (Impact Factor: 1.23). 03/2011; 22(4):257-68. DOI: 10.1016/j.jana.2010.11.004
Source: PubMed

ABSTRACT Symptom burden has been identified as a predictor of medication adherence, but little is known about which symptoms are most strongly implicated. This study examines self-reported medical adherence in relation to demographic, clinical, and symptom characteristics among 302 adults living with HIV. Only 12% reported missing medication during the 3-day assessment, but 75% gave at least one reason for missing it in the previous month. Poor adherence was associated with higher viral load and greater symptom burden. Trouble sleeping and difficulty concentrating were strongly associated with poor adherence. Given that "forgetting" was the most common reason for missing medication and nearly one third reported sleeping through dose time, future research should examine the influence of sleep disturbance on adherence. Effective management of common symptoms, such as sleep disturbance, fatigue, and gastrointestinal side-effects of medications may result in better adherence, as well as improved clinical outcomes and quality of life.

Download full-text


Available from: Caryl Gay, Jul 18, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Microbial translocation within the context of HIV disease has been described as one of the contributing causes of inflammation and disease progression in HIV infection. HIV-associated symptoms have been related to inflammatory markers and sCD14, a surrogate marker for microbial translocation, suggesting a plausible link between microbial translocation and symptom burden in HIV disease. Similar pathophysiological responses and symptoms have been reported in inflammatory bowel disease (IBD). We provide a comprehensive review of microbial translocation, HIV-associated symptoms, and symptoms connected with inflammation. We identify studies showing a relationship among inflammatory markers, sCD14, and symptoms reported in HIV disease. A conceptual framework and rationale to investigate the link between microbial translocation and symptoms is presented. The impact of inflammation on symptoms supports recommendations to reduce inflammation as part of HIV symptom management. Research in reducing microbial translocation-induced inflammation is limited, but needed, to further promote positive health outcomes among HIV-infected patients.
    Journal of the Association of Nurses in AIDS Care 11/2014; 25(6). DOI:10.1016/j.jana.2014.07.004 · 1.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: As compared to metallic skeletal restorations, calcium phosphate ceramics offer superior properties, including: strong chemical resistance to environmental and microbial corrosion, compositionally controllable in vivo biological performance (bioactivity, solubility), high wear resistances, and excellent mechanical properties. Unfortunately, these ideal properties have not been obtained because commercial calcium phosphate ceramics vary notably in purity, crystal structure, and particle size. As a novel processing solution, a two-step processing technique was developed to result in a wide compositional range of pure, stoichiometric calcium phosphates [xCaO·P<sub>2 </sub>O<sub>5</sub>; x=3.0-3.3], The first step involved the low temperature (&les;5°C) reaction between CaO and high purity phosphoric acid [H<sub>3</sub>PO<sub>4</sub>, Na-2 ppb]. After eliminating soluble reactants and impurity calcium phosphate phases, a crystalline calcium orthophosphate [CaHPO<sub>4</sub>] powder was obtained in 61.1% yields. Thermal analysis (TGA, DTA), X-ray diffraction (XRD) and optical pyncnometry indicated that this product endothermically transforms at 460°C [92.7% yield] into a highly pure, crystalline calcium pyrophosphate (2CaO·P<sub>2</sub>O<sub>5</sub>) with an average particle size of 3.8 μm (2-15 μm). In the second step, 2CaO·P<sub>2</sub>O<sub>5</sub> was intimately blended with low alkali impurity CaCO<sub>3</sub> (1,1,3 mole%) and calcined in pure oxygen atmospheres to result in controlled composition calcium phosphate ceramics (xCaO·P<sub>2</sub>O<sub>5</sub>). To demonstrate the potential of this technique, crystalline oxyapatite ceramics (3.33CaO·P<sub>2</sub>O<sub>5</sub>) were obtained in high yields (85.8%) at temperatures exceeding 1000°C with average crystalline particle sizes of 3.8 μm (2-20 μm). Petrographic, refractive index characterization of the ceramic precursor powders indicate that in all stages of processing, high purity, spherical powders of uniform crystallinity and particle size were obtained. In contrast to conventional calcium phosphate ceramics, this novel processing technique results in crystalline precursor powders of high purity, controlled composition, uniform crystal structure, and homogeneous particle size distribution. These ceramic precursor powders can be used with conventional ceramic processing techniques to result in products with the improved properties required for clinical success
    Biomedical Engineering Conference, 1997., Proceedings of the 1997 Sixteenth Southern; 05/1997
  • [Show abstract] [Hide abstract]
    ABSTRACT: Limited data exist on tolerability of antiretroviral therapy (ART) in older HIV-infected patients compared to their younger counterparts. There is also concern for overlap of ART toxicities with concomitant conditions potentially leading to an increased burden of ART-related adverse drug reactions (ADRs). A prospective, descriptive-comparative study was conducted to compare incidence and severity of ADRs secondary to ART in older (≥ 50 years) versus younger (<50 years) HIV-infected patients. No differences were found in the presence or severity of subjective or objective ADRs between groups. The burden of intolerance appeared to be high for certain ADRs in both age groups. Regardless of age, subjects with certain concomitant illnesses had higher rates of potential ADRs. Providers need to be aware of patient characteristics that lead to increased rates of ART intolerance; for patients with an increased comorbidity burden, providers need to be attentive to the potential impact on ART tolerability.
    The Journal of the Association of Nurses in AIDS Care: JANAC 11/2011; 23(5):397-408. DOI:10.1016/j.jana.2011.09.005 · 1.23 Impact Factor